Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
Identifieur interne : 001C68 ( Main/Exploration ); précédent : 001C67; suivant : 001C69Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
Auteurs : Shibo Jiang [États-Unis] ; Maria Elena Bottazzi ; Lanying Du ; Sara Lustigman ; Chien-Te Kent Tseng ; Elena Curti ; Kathryn Jones ; Bin Zhan ; Peter J. HotezSource :
- Expert review of vaccines [ 1744-8395 ] ; 2012.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Animaux, Anticorps antiviraux (immunologie), Anticorps neutralisants (immunologie), Antigènes viraux (immunologie), Composés de l'aluminium (administration et posologie), Essais cliniques comme sujet, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Humains, Lipide A (administration et posologie), Phosphates (administration et posologie), Protéines de l'enveloppe virale (immunologie), Structure tertiaire des protéines, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (immunologie), Vaccins sous-unitaires (immunologie), Vaccins synthétiques (immunologie), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
- MESH :
- administration et posologie : Adjuvants immunologiques, Composés de l'aluminium, Lipide A, Phosphates.
- immunologie : Anticorps antiviraux, Anticorps neutralisants, Antigènes viraux, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins sous-unitaires, Vaccins synthétiques, Virus du SRAS.
- pathogénicité : Virus du SRAS.
- Animaux, Essais cliniques comme sujet, Glycoprotéine de spicule des coronavirus, Humains, Structure tertiaire des protéines, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Aluminum Compounds (administration & dosage), Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), Antigens, Viral (immunology), Clinical Trials as Topic, Humans, Lipid A (administration & dosage), Membrane Glycoproteins (immunology), Phosphates (administration & dosage), Protein Structure, Tertiary, SARS Virus (immunology), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccines, Subunit (immunology), Vaccines, Synthetic (immunology), Viral Envelope Proteins (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Aluminum Compounds, Lipid A, Phosphates.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Antigens, Viral, Membrane Glycoproteins, Vaccines, Subunit, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Clinical Trials as Topic, Humans, Protein Structure, Tertiary, Spike Glycoprotein, Coronavirus.
Abstract
A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.
DOI: 10.1586/erv.12.126
PubMed: 23252385
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001273
- to stream PubMed, to step Curation: 001273
- to stream PubMed, to step Checkpoint: 001298
- to stream Ncbi, to step Merge: 002601
- to stream Ncbi, to step Curation: 002601
- to stream Ncbi, to step Checkpoint: 002601
- to stream Main, to step Merge: 001C83
- to stream Main, to step Curation: 001C68
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.</title><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Lustigman, Sara" sort="Lustigman, Sara" uniqKey="Lustigman S" first="Sara" last="Lustigman">Sara Lustigman</name></author><author><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name></author><author><name sortKey="Curti, Elena" sort="Curti, Elena" uniqKey="Curti E" first="Elena" last="Curti">Elena Curti</name></author><author><name sortKey="Jones, Kathryn" sort="Jones, Kathryn" uniqKey="Jones K" first="Kathryn" last="Jones">Kathryn Jones</name></author><author><name sortKey="Zhan, Bin" sort="Zhan, Bin" uniqKey="Zhan B" first="Bin" last="Zhan">Bin Zhan</name></author><author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:23252385</idno><idno type="pmid">23252385</idno><idno type="doi">10.1586/erv.12.126</idno><idno type="wicri:Area/PubMed/Corpus">001273</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001273</idno><idno type="wicri:Area/PubMed/Curation">001273</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001273</idno><idno type="wicri:Area/PubMed/Checkpoint">001298</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001298</idno><idno type="wicri:Area/Ncbi/Merge">002601</idno><idno type="wicri:Area/Ncbi/Curation">002601</idno><idno type="wicri:Area/Ncbi/Checkpoint">002601</idno><idno type="wicri:Area/Main/Merge">001C83</idno><idno type="wicri:Area/Main/Curation">001C68</idno><idno type="wicri:Area/Main/Exploration">001C68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.</title><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Lustigman, Sara" sort="Lustigman, Sara" uniqKey="Lustigman S" first="Sara" last="Lustigman">Sara Lustigman</name></author><author><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name></author><author><name sortKey="Curti, Elena" sort="Curti, Elena" uniqKey="Curti E" first="Elena" last="Curti">Elena Curti</name></author><author><name sortKey="Jones, Kathryn" sort="Jones, Kathryn" uniqKey="Jones K" first="Kathryn" last="Jones">Kathryn Jones</name></author><author><name sortKey="Zhan, Bin" sort="Zhan, Bin" uniqKey="Zhan B" first="Bin" last="Zhan">Bin Zhan</name></author><author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name></author></analytic><series><title level="j">Expert review of vaccines</title><idno type="eISSN">1744-8395</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Aluminum Compounds (administration & dosage)</term><term>Animals</term><term>Antibodies, Neutralizing (immunology)</term><term>Antibodies, Viral (immunology)</term><term>Antigens, Viral (immunology)</term><term>Clinical Trials as Topic</term><term>Humans</term><term>Lipid A (administration & dosage)</term><term>Membrane Glycoproteins (immunology)</term><term>Phosphates (administration & dosage)</term><term>Protein Structure, Tertiary</term><term>SARS Virus (immunology)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Subunit (immunology)</term><term>Vaccines, Synthetic (immunology)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps neutralisants (immunologie)</term><term>Antigènes viraux (immunologie)</term><term>Composés de l'aluminium (administration et posologie)</term><term>Essais cliniques comme sujet</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Humains</term><term>Lipide A (administration et posologie)</term><term>Phosphates (administration et posologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins sous-unitaires (immunologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Aluminum Compounds</term><term>Lipid A</term><term>Phosphates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Antigens, Viral</term><term>Membrane Glycoproteins</term><term>Vaccines, Subunit</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Composés de l'aluminium</term><term>Lipide A</term><term>Phosphates</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Antigènes viraux</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins sous-unitaires</term><term>Vaccins synthétiques</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Humans</term><term>Protein Structure, Tertiary</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Essais cliniques comme sujet</term><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name><name sortKey="Curti, Elena" sort="Curti, Elena" uniqKey="Curti E" first="Elena" last="Curti">Elena Curti</name><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name><name sortKey="Jones, Kathryn" sort="Jones, Kathryn" uniqKey="Jones K" first="Kathryn" last="Jones">Kathryn Jones</name><name sortKey="Lustigman, Sara" sort="Lustigman, Sara" uniqKey="Lustigman S" first="Sara" last="Lustigman">Sara Lustigman</name><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name><name sortKey="Zhan, Bin" sort="Zhan, Bin" uniqKey="Zhan B" first="Bin" last="Zhan">Bin Zhan</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23252385
|texte= Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23252385" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |